Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

References

• RaneSGReddyEPJanus kinases: components of multiple signaling pathwaysOncogene200019495662567911114747
   PubMed Web of Science ®Google Scholar
• HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
   PubMed Web of Science ®Google Scholar
• WilliamADLeeACBlanchardSDiscovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphomaJ Med Chem201154134638465821604762
   PubMed Web of Science ®Google Scholar
• HartSGohKCNovotny-DiermayrVSB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesLeukemia201125111751175921691275
   PubMed Web of Science ®Google Scholar
• HartSGohKCNovotny-DiermayrVPacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaBlood Cancer J2011111e4422829080
   PubMed Web of Science ®Google Scholar
• VerstovsekSDeegHJOdenikeOPhase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosisProceedings of the 53rd Annual Meeting of the American Society of HematologyDecember 10–13, 2011Chicago, IL Abstract 3082
   Google Scholar
• VerstovsekSOdenikeOScottBPhase 1 dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/poly-cythemia vera myelofibrosisProceedings of the 51st Annual Meeting of the American Society of HematologyDecember 5–8, 2009New Orleans, LA Abstract 3905
   Google Scholar
• VerstovsekSPassamontiFRambaldiAA phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyureaProceedings of the 51st Annual Meeting of the American Society of HematologyDecember 5–8, 2009New Orleans, LA Abstract 311
   Google Scholar
• YounesAFanaleMMclaughlinPPhase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activityProceedings of the 51st Annual Meeting of the American Society of HematologyDecember 5–8, 2009New Orleans, LA Abstract 588
   Google Scholar
• YounesAFanaleMMclaughlinPCopelandARZhuJDe Castro FariaSPhase 1 study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypesProceedings of the 53rd Annual Meeting of the American Society of HematologyDecember 10–13, 2011Chicago, IL Abstract 2830
   Google Scholar
• KomrokjiRSWadleighMSeymourJFResults of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosisProceedings of the 53rd Annual Meeting of the American Society of HematologyDecember 10–13, 2011Chicago, IL Abstract 282
   Google Scholar
• VerstovsekSMesaRAGotlibJLong-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-IProceedings of the 55th Annual Meeting of the American Society of HematologyDecember 7–10, 2013New Orleans, LA Abstract 2830
   Google Scholar
• MesaRAEgyedMSzokeAResults of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)Proceedings of the 2015 Annual Meeting of the American Society of Clinical OncologyMay 29–June 2, 2015Chicago, IL
   Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• LuXLevineRTongWExpression of a homodimeric type 1 cytokine receptor is required for JAK2V617F-mediated transformationProc Natl Acad Sci U S A200510252189621896716365288
   PubMed Web of Science ®Google Scholar
• RumiEPietraDPascuttoCClinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisBlood201412471062106924986690
   PubMed Web of Science ®Google Scholar
• ReillyJTFLT3 and its role in the pathogenesis of acute myeloid leukaemiaLeuk Lymphoma20034411712691136
   PubMed Web of Science ®Google Scholar
• TickenbrockLMuller-TidowCBerdelWEServeHEmerging Flt3 kinase inhibitors in the treatment of leukaemiaExpert Opin Emerg Drugs200611115316516503833
   PubMedGoogle Scholar
• SteensmaDPMcClureRFKarpJEJAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplainedLeukemia200620697197816598306
   PubMed Web of Science ®Google Scholar
• AnastassiadisTDeaconSWDevarajanKMaHPetersonJRComprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNat Biotechnol201129111039104522037377
   PubMed Web of Science ®Google Scholar
• YeeTWHastieTJReduced-rank vector generalized linear modelsStat Model200331541
   Web of Science ®Google Scholar
• van der LooMPJDistribution based outlier detection for univariate dataDiscussion paper 10003The HagueStatistics Netherland2010
   Google Scholar
• RhyasenGWBolanosLFangJTargeting IRAK1 as a therapeutic approach for myelodysplastic syndromeCancer Cell20132419010423845443
   PubMed Web of Science ®Google Scholar
• Puig de la BellacasaRKarachaliouNEstrada-TejedorRTeixidoJCostaCBorrellJIALK and ROS1 as a joint target for the treatment of lung cancer: a reviewTransl Lung Cancer Res201322728625806218
   PubMedGoogle Scholar
• HendersonMCGonzalesIMAroraSHigh-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cellsMol Cancer Res20119672473221536687
   PubMed Web of Science ®Google Scholar
• PolkALuYWangTColony-stimulating Factor-1 receptor is required for nurse-like cell survival in chronic lymphocytic leukemiaClin Cancer Res Epub2016622
   Web of Science ®Google Scholar
• ClearyMMThompsonRMahmoodSPacritinib, a dual FLT3/JAK2 inhibitor, reduces IRAK-1 signaling in acute myeloid leukemiaProceedings of the 57th Annual Meeting of the American Society of HematologyDecember 5–8, 2015Orlando, FL Abstract 570
   Google Scholar
• Jakafi® (ruxolitinib) tablets, for oral use [prescribing information]Wilmington, DEIncyte Corporation2011
   Google Scholar
• GotlibJJAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedsideHematology Am Soc Hematol Educ Program2013201352953724319228
   PubMed Web of Science ®Google Scholar
• GowinKEmanuelRGeyerHMesaRAThe new landscape of therapy for myelofibrosisCurr Hematol Malig Rep20138432533224101258
   PubMed Web of Science ®Google Scholar
• FurqanMMukhiNLeeBLiuDDysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical applicationBiomark Res201311524252238
   PubMedGoogle Scholar
• PardananiALashoTSmithGBurnsCJFantinoETefferiACYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsLeukemia20092381441144519295546
   PubMed Web of Science ®Google Scholar
• ZhouTGeorgeonSMoserRMooreDJCaflischAHantschelOSpecificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)Leukemia201428240440723823659
   PubMed Web of Science ®Google Scholar
• LooyengaBDHutchingsDCherniIKingsleyCWeissGJMackeiganJPSTAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinomaPLoS One201272e3082022319590
   PubMed Web of Science ®Google Scholar
• HeineAHeldSADaeckeSNThe JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivoBlood201312271192120223770777
   PubMed Web of Science ®Google Scholar
• SchonbergKRudolphJVonnahmeMJAK inhibition impairs NK cell function in myeloproliferative neoplasmsCancer Res201575112187219925832652
   PubMed Web of Science ®Google Scholar
• TefferiARuxolitinib targets DCs: for better or worse?Blood201312271096109723950171
   PubMed Web of Science ®Google Scholar
• GhoreschiKLaurenceAO’SheaJJSelectivity and therapeutic inhibition of kinases: to be or not to be?Nat Immunol200910435636019295632
   PubMed Web of Science ®Google Scholar
• BoldinMPTaganovKDRaoDSmiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in miceJ Exp Med201120861189120121555486
   PubMed Web of Science ®Google Scholar
• ZhaoJLRaoDSBoldinMPTaganovKDO’ConnellRBaltimoreDNF-κB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignanciesProc Natl Acad Sci U S A2011108229184918921576471
   PubMed Web of Science ®Google Scholar
• WangJQJeelallYSFergusonLLHorikawaKToll-like receptors and cancer: MYD88 mutation and inflammationFront Immunol2014536725132836
   PubMed Web of Science ®Google Scholar
• AgarwalABummTGCorbinASAbsence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative diseaseBlood200811251960197018559973
   PubMed Web of Science ®Google Scholar
• McClearyMMThompsonRMahmoodSPacritinib, a dual FLT3/JAK2 inhibitor, reduces Irak-1 signaling in acute myeloid leukemiaProceedings of the 57th Annual Meeting of the American Society of HematologyDecember 5–8, 2015Orlando, FL Abstract 570
   Google Scholar
• MaYRixLRZhangQPacritinib (PAC) synergistically potentiates azacitidine (5AZA) cytotoxicity in chronic myelomonocytic leukemia (CMML)Proceedings of the 57th Annual Meeting of the American Society of HematologyDecember 5–8, 2015Orlando, FL Abstract 1658
   Google Scholar
• UgelSDe SanctisFMandruzzatoSBronteVTumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophagesJ Clin Invest201512593365337626325033
   PubMed Web of Science ®Google Scholar
• BurgerJATsukadaNBurgerMZvaiflerNJDell’AquilaMKippsTJBlood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1Blood20009682655266311023495
   PubMed Web of Science ®Google Scholar
• TapWDWainbergZAAnthonySPStructure-guided blockade of csf1r kinase in tenosynovial giant-cell tumorN Engl J Med2015373542843726222558
   PubMed Web of Science ®Google Scholar
• PaniaguaRTChangAMarianoMMc-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritisArthritis Res Ther2010121R3220181277
   PubMed Web of Science ®Google Scholar
• BlonskaMAgarwalNKVegaFShaping of the tumor microenvironment: Stromal cells and vesselsSemin Cancer Biol20153431325794825
   PubMed Web of Science ®Google Scholar
• BorgeMNanniniPRMorandePECXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patientsCancer Immunol Immunother201362111312422842611
   PubMed Web of Science ®Google Scholar
• BorgeMRemes LenicovFNanniniPRThe expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406J Immunol201419363165317425127862
   PubMed Web of Science ®Google Scholar
• BurgerJAKippsTJChemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cellsLeuk Lymphoma200243346146612002747
   PubMed Web of Science ®Google Scholar
• KnapperSGrechACahalinPAn evaluation of the tyrosine kinase inhibitor pacritinib in patients with relapsed FLT-3 mutated acute myeloid leukaemia (the UK NCRI AML 17 study)Poster presented at: 21st Congress of the European Hematology AssociationJune 9–12, 2016Copenhagen, Denmark Abstract P184
   Google Scholar